Immune Checkpoint Inhibitor‐Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles
- 26 March 2026
- journal article
- Published by Wiley in Experimental Dermatology
- Vol. 35 (4) , e70241
Abstract
Bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI‐BP) is a rare immune‐related adverse event that affects patient prognosis and management; however, comparative data between ICI‐BP and non‐ICI BP, especially the dynamic changes of antibodies remain scarce. Therefore, we conducted this study to compare clinical presentation, immunological profile, treatment, management, and outcomes of ICI‐BP versus non‐ICI BP. This was a retrospective, single‐centre cohort study of consecutive patients between 2019 and 2025. Patients with ICI‐BP (Group A) were compared with Group B (BP with concurrent malignancy but no ICI exposure) and Group C (classic BP). There were 34, 10, and 68 patients enrolled in Groups A, B, and C, respectively (median follow‐up 24.5 months, IQR 10.8–50.0). ICI‐BP presented at a younger age (median, 59.0 years; IQR, 53.3–69.5; p < 0.001) and showed a marked male predominance (88.2%; p = 0.003). A transient, albeit non‐significant, rise in anti‐BP180 reactivity was observed during the first 2 months in ICI‐BP. Systemic glucocorticoids were required more frequently in ICI‐BP, and IL‐4 inhibitors demonstrated superior potency in accelerating BP180 antibody decline compared to non‐systematic therapy. Tumour response rates were similar between Groups A and B, as was mortality across the three groups. In conclusion, ICI‐BP differs from non‐ICI BP in clinical and immunological features and more often necessitates systemic glucocorticoid therapy, while IL‐4 inhibitors potentially expedite the reduction of anti‐BP180 antibodies in ICI‐BP patients.Keywords
This publication has 25 references indexed in Scilit:
- Three distinct clinical phenotypes of immune checkpoint inhibitor–induced bullous pemphigoid predict divergent treatment responses and outcomesJournal of the American Academy of Dermatology, 2025
- Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous PemphigoidJAMA Dermatology, 2025
- Bullous pemphigoid: A practical approach to diagnosis and management in the modern eraJournal of the American Academy of Dermatology, 2025
- Cancer situation in China: an analysis based on the global epidemiological data released in 2024Cancer Communications, 2024
- Comparative analysis of cancer statistics in China and the United States in 2024Chinese Medical Journal, 2024
- Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatmentBritish Journal of Dermatology, 2023
- Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With CancerJAMA Dermatology, 2022
- Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With MelanomaJAMA Network Open, 2021
- High Expression of Collagen XVII Compensates for its Depletion Induced by Pemphigoid IgG in the Oral MucosaJournal of Investigative Dermatology, 2018
- Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cellsNature Communications, 2016